S
SYNCOMF
vs
B
BSE Sensex 30
Over the past 12 months, SYNCOMF has underperformed BSE Sensex 30, delivering a return of -22% compared to the BSE Sensex 30's +10% growth.
Stocks Performance
SYNCOMF vs BSE Sensex 30
Performance Gap
SYNCOMF vs BSE Sensex 30
Performance By Year
SYNCOMF vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Syncom Formulations (India) Ltd
Glance View
Syncom Formulation India Ltd. is a pharmaceutical company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Indore, Madhya Pradesh. The firm manufactures and markets more than 300 pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquid orals, liquid vials and ampoule injections and dry vial injections, dry syrups, ointments and inhalers. Its segments include Pharmaceuticals Drugs & Formulations, Trading of Commodities and Renting of property. Its product categories include tablets, capsules, ointments, injections, liquid-oral and packaging variants. The company offers various products, including generics, alpha adrenoceptor agonist, analgesic, antipyretic, anti-inflammatory, anti-ulcer agents, antibiotic, antidepressant, antiviral, cephelo sporins, cortico steroid, estrogen, cough suppressant and sedative anticonvulsant, among others. The firm operates in more than 15 countries across the world.
